DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for gelatinous drop-like corneal dystrophy — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGelatinous drop-like corneal dystrophy maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for gelatinous drop-like corneal dystrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tumor associated calcium signal transducer 2 (TACSTD2) — TACSTD2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7E5N · 3.2 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Gelatinous drop-like corneal dystrophy is a rare autosomal recessive disorder characterised by subepithelial and stromal amyloid deposits. It is relatively common in Japan and usually presents in the first two decades of life with subepithelial nodular lesions that later coalesce into mulberry-like opacities. The condition is caused by a dysfunction of the epithelial barrier, leading to protein deposits most likely originating from tear fluid. The responsible gene, M1S1, is mapped to the short arm of chromosome 1, but the possible aetiology of the disease remains unclear.
Histopathology of a recurrent case operated on seven years after original surgery showed an abnormally thick epithelium with many intercellular spaces at all levels, though cell-cell contact via desmosomes was still evident. An in vitro tracer was able to penetrate the most superficial tight junctions of the corneal epithelium. Basal epithelial cells were not columnar, and numerous spike-like projections protruded into the underlying amyloid and collagenous tissue. Duplication of a discontinuous epithelial basement membrane was noted, and collagen often coexisted with extensive amyloid deposition. Some features not previously reported in primary disease were observed: abnormally large, sulfated proteoglycan filaments interspersed with amyloid and underlying stroma, long-spacing collagen, permeability of epithelial tight junctions, and basement membrane duplication.
Various surgical modalities have been attempted, but recurrence remains a major challenge. Corneal transplantation is described as the only treatment for visual rehabilitation. In two clinical cases, where topical lubricating and anti-inflammatory therapy proved insufficient, penetrating allogenic limbokeratoplasty was considered as a curative approach. The disease course is typically protracted and prone to frequent relapses. Patients typically present under age 20 with drop-like corneal lesions showing high fluorescein uptake.
What is still missing is a clear understanding of the aetiology beyond the M1S1 gene mutation, any drug therapy that prevents or delays recurrence after surgery, and a trial design that can test interventions in a disease this rare without relying solely on surgical case series. Patient stratification by mutation type or by the specific barrier defect seen in histology has not been attempted.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Ophthalmology · 2016 · 30 citations
Gelatinous drop-like corneal dystrophy: a review
AbstractGelatinous drop-like corneal dystrophy (GDLD) is a rare autosomal recessive form of corneal dystrophy characterised by subepithelial and stromal amyloid deposits. It is relatively common in Japan. It usually presents in the first two decades of life with subepithelial nodular lesions that later coalesce to form mulberry-like opacities. Although various surgical modalities have been attempted, recurrence remains a major challenge.
Histopathology of Recurrent Gelatinous Drop-Like Corneal Dystrophy
AbstractPURPOSE: To elucidate more fully the histopathology of gelatinous drop-like corneal dystrophy in a case that recurred and was operated on 7 years after the original surgery. METHODS: Transmission electron microscopy, including the use of cuprolinic blue to image sulfated proteoglycans, and horseradish peroxidase as a marker for in vitro epithelial permeability. RESULTS: Our patient's epithelium was often abnormally thick, and many intercellular spaces were present at all levels, although cell-cell contact via desmosomes was also evident. Horseradish peroxidase, when used as an in vitro tracer, was able to penetrate the most superficial tight junctions of the corneal epithelium. Basal epithelial cells were not columnar, and numerous spike-like projections protruded into the underlying amyloid/collagenous tissue from the basal epithelium. Beneath this, duplication of a discontinuous epithelial basement membrane was noted. In this region, collagen often coexisted with amyloid, the deposition of which was extensive. As in some other corneal pathologies, long-spacing collagen was detected. The association of small proteoglycans with collagen was unremarkable, although some abnormally large, sulfated proteoglycan filaments were interspersed with the amyloid and underlying stroma. CONCLUSION: Recurrent gelatinous drop-like corneal dystrophy shares several histopathologic features with its primary counterpart, although some features, such as the presence of abnormally large, sulfated proteoglycans and long-spacing collagen, the permeability of the epithelial tight junctions, and the duplication of the epithelial basement membrane, have not been reported previously.
AbstractGelatinous drop-like corneal dystrophy is a very rare autosomal recessive disease classified as an epithelial and subepithelial corneal dystrophy. Patients typically present under the age of 20 with drop-like corneal lesions showing high corneal fluorescein uptake. Their disease course is typically protracted and prone to frequent relapses. The condition is caused by a dysfunction of the epithelial barrier, leading to protein deposits most likely originating from tear fluid. Histology typically shows subepithelial amyloid deposits with corresponding defects of Bowman's layer and epithelial atrophy. Where topical lubricating and anti-inflammatory therapy proves insufficient, penetrating allogenic limbokeratoplasty can be considered in a curative approach. In this report, we present disease courses of 2 unrelated patients. Current findings on pathogenesis are discussed.
[Current advances in gene diagnosis and therapy of gelatinous drop-like corneal dystrophy].
AbstractGelatinous drop-like corneal dystrophy (GDLD) is an autosomal recessive hereditary disease, which may result in bilateral loss of vision. The gene responsible for GDLD, M1S1 is mapped on the short arm of chromosome 1 (1p), but the possible etiology of this disease remains unclear. Corneal transplantation is the only treatment for visual rehabilitation. The detection of the mutations of the M1S1 gene and the possible etiological involvement of the amyloid deposits are discussed. The current literatures are extensively reviewed in this article.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
